CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Jun. 30, 2018	Jun. 30, 2017
Revenues	$ 0	$ 295	$ 2,156	$ 3,091
Costs and expenses:
Costs of goods sold	0	0	613	483
Research and development	93,887	254,871	99,283	51,776
Sales and marketing	19,834	26,459	6,822	873
General and administrative	30,814	43,803	36,485	29,109
Total costs and expenses	144,535	325,133	143,203	82,241
Operating loss	(144,535)	(324,838)	(141,047)	(79,150)
Changes in fair market value of warrant liabilities	1,404	0	(108,636)	(61,074)
Warrant related expenses	0	0	0	(7,649)
Interest expense	(20,017)	(40,337)	(23,255)	(5,480)
Interest and other income	6,106	7,856	5,493	431
Loss on induced exchanges of debt	(897)	0	(13,005)	0
Other financing expenses	0	0	0	(347)
Insurance reimbursement	190	0	6,638	0
Foreign currency transaction gain, net	0	0	81	23
Loss before income tax	(157,749)	(357,319)	(273,731)	(153,246)
Income tax expense	0	0	(156)	(20)
Net loss	(157,749)	(357,319)	(273,887)	(153,266)
Net loss attributable to noncontrolling interest	(81)	(129)	(50)	(60)
Net loss attributable to Immunomedics, Inc. stockholders	$ (157,668)	$ (357,190)	$ (273,837)	$ (153,206)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)	$ (0.84)	$ (1.84)	$ (1.78)	$ (1.47)
Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)	188,554	193,617	153,475	104,536
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (8)	$ 174	$ (105)	$ (62)
Unrealized gain (loss) on securities available for sale	10	(391)	55	(109)
Other comprehensive income (loss), net of tax:	2	(217)	(50)	(171)
Comprehensive loss	(157,747)	(357,536)	(273,937)	(153,437)
Comprehensive loss attributable to noncontrolling interest	(81)	(129)	(50)	(60)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	(157,666)	(357,407)	(273,887)	(153,377)
Product sales
Revenues	0	0	1,501	2,443
License fee and other revenues
Revenues	0	295	330	284
Research and development
Revenues	$ 0	$ 0	$ 325	$ 364